Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results in a Phase III Transient Insomnia Clinical Trial
16th Nov 2006, 16:03 GMT
VEC-162 Demonstrates Statistically Significant Improvement vs. Placebo in Measures of Sleep Onset and Sleep Maintenance Validates Unique Mechanism of Action and Positioning for Unmet Medical Needs
Latest news from Neurology News from StratCenter.com:
- Alzheimer's Foundation of America to Hold Nat'l Memory Screening Day
- Neurologix Announces Q3 Results
- Kensey Nash Announces Commencement of Carotid Pivotal Trial for TriActiv ProGuard System
- New Study Finds Everyday Activities Trigger Smoking Cravings
- Neurobiological Technologies Review Issued by Scimitar Equity Research
- AQA Adopts Additional Standard Quality Measures for Practitioners in 25 Surgical and Medical Specialties
- StemCells' product transplanted in early clinical trial
- Acorda Therapeutics Added to NASDAQ Biotech Index
- StemCells Begins Study on Rare Disease
- StemCells Announces 1st Human Neural Stem Cell Transplant